• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

SIR: Long-Term Pain Relief Found with Vertebroplasty

Article

SEATTLE -- Percutaneous vertebroplasty reduces pain of collapsed vertebra without increasing risk of new fractures over the long term, Italian researchers said here.

SEATTLE, March 8 -- Percutaneous vertebroplasty reduces pain of collapsed vertebrae without increasing risk of new fractures over the long term, according to Italian researchers.

Among 1,005 consecutive patients who had a cement injected into frail vertebrae, pain dropped a clinically relevant 6.5 points on the 11-point visual analog scale (P

After three to 51 months of follow-up, 13.4% of patients with osteoporosis had a new vertebral fracture (average 9.4 months after vertebroplasty). Most new fractures were in vertebra adjacent to those strengthened (68.8%, P=0.0004) without a significant difference in occurrence above or below the treated vertebrae (P=0.1).

The rate of retreatment for fracture compared favorably to published rates for placebo (18.9%, P=0.09) and medical osteoporosis treatment with 20 ?G teriparatide (Forteo, 11.2%, P=0.3) or 40 ?G teriparatide (10.4%, P=0.17).

The complication findings were:

  • 2.3% of patients had a minor complication (16 asymptomatic pulmonary embolism, six nerve root irritation, and one needle tip rupture),
  • 0.3% had a major complication (one each for subcutaneous ematoma, local skin infection, and spondylitis),
  • 31.2% of patients had asymptomatic leakage of the vertebroplasty material into the veins (36.8% of vertebrae),
  • 15.5% had asymptomatic leakage into the disc.

Dr. Anselmetti chalked up the "very low" complication rate to their use of state-of-the-art imaging systems.

"As our data do not show any increased risk of a new fracture compared to placebo and medical therapy," he said, "a prospective randomized trials have to be performed to assess if [percutaneous vertebroplasty] in the future will be consider as 'conventional therapy' in the treatment of painful vertebral fractures."

Related Videos
Infectious disease specialist talks about COVID-19 vaccine development
COVID 19 impact on healthcare provider mental health
Physician mental health expert discusses impact of COVID-19 on health care workers
Related Content
© 2024 MJH Life Sciences

All rights reserved.